Vyome Holdings, Inc. @VyomeInc

Globally, an estimated 1M patients develop malignant fungating wounds (MFW), a condition with no FDA-approved treatments for malodor. Vyome Holdings (NASDAQ: HIND) reports Phase 2 interim data showing PROM improvements for VT-1953 Gel #Biotech #Oncology #MFW #NASDAQ

🚀 Vyome Holdings (NASDAQ: HIND) reports positive Phase 2 interim data for VT-1953 in malignant fungating wounds (MFW) – reducing pain & odor, improving QoL! 🎤 Join Co-founder Dr. Shiladitya Sengupta on 09/08, 5 PM ET for a live web discussion. 🔗 Read more #Biotech #Oncology

🇮🇳 Marking Indian Independence Day with a new chapter. 🏥 Vyome Therapeutics, previously ReShape Lifesciences, is building healthcare innovation across India and the U.S. 🎉 Now trading as $HIND. Congrats!

keyboard_arrow_left Previous keyboard_arrow_right Next

Kicked off the morning with the $HIND opening bell ceremony @NasdaqExchange 🇮🇳

keyboard_arrow_left Previous keyboard_arrow_right Next

Ringing the @Nasdaq #OpeningBell on India’s Independence Day to mark our first day of trading as $HIND. Grateful to our team, partners, and patients as we advance therapies for immuno-inflammatory and rare diseases. Watch here: nasdaq.com/events/vyome-t…

Today we ring the @Nasdaq Opening Bell to mark our first day of trading as $HIND - on India’s Independence Day. Honoring the US–India innovation corridor as we advance treatments for immuno-inflammatory & rare diseases. Jai Hind! 🇮🇳🇺🇸 businesswire.com/news/home/2025…

We're set to ring the opening bell at Nasdaq tom & start trading as $HIND on Indian Independence Day! Tune in & cheer us on. Bullish on US-India relationship - the confetti will be orange, white, and green. Jai $HIND & God Bless America! 🇺🇸🇮🇳 @VyomeInc businesswire.com/news/home/2025…

Unveiling our new logo! A powerful convergence of the US and India, and a commitment to create value for all stakeholders. $RSLS $HIND

Early results from our Phase 2 study of VT-1953 show promising improvements for patients with Malignant Fungating Wounds (MFW). Significant reductions in malodor and pain highlight the potential to address this critical unmet need. $HIND $RSLS Learn more: tinyurl.com/zpbdhnek

Big results from @VyomeInc on the safety and efficacy of its lead product for Malignant Fungating Wound. Sets up a very interesting year ahead $HIND $RSLS einnews.com/pr_news/778675…

“I regularly see cancer patients who are struggling with the symptoms of MFW...this kind of efficacy could be transformative for these patients. This is a huge unmet need”, said Dr. Sant Chawla MD, a leading oncologist...who was not involved with the trial. $HIND $RSLS @VyomeInc

Krishna K. Gupta @KrishnaKGupta

8 months ago

“I regularly see cancer patients who are struggling with the symptoms of MFW...this kind of efficacy could be transformative for these patients. This is a huge unmet need”, said Dr. Sant Chawla MD, a leading oncologist...who was not involved with the trial. $HIND $RSLS @VyomeInc

0 2 2 1K 0

MFW is a horrible complication afflicting almost 5-14% of advanced cancer patients. There are no approved medicines. Today Vyome Therapeutics announced early results from a Ph2 study in MFW @AmericanCancer einnews.com/pr_news/778675…

"I don’t think there is anything out there big enough to threaten the trajectory of the U.S.-India relations...This is incredibly resilient and almost inevitable" - current US Ambassador Garcetti. Great article in the @nytimes yesterday. $HIND $RSLS nytimes.com/2025/01/18/wor…

An update for $RSLS shareholders on the merger with Vyome $HIND as reported by ReShape - it's on track! By leveraging the U.S.-India innovation corridor, we’re creating a powerhouse for global healthcare solutions finance.yahoo.com/news/reshape-l…

$RSLS shareholders and interested $HIND shareholders/followers, we will be sharing more about Vyome on an ongoing basis now. Stay tuned!